Avid Bioservices Inc (CDMO)

[biopharm]

Thanks to all those doing some due diligence and easy to see and realize David Carbone is Peregrines Pharmaceuticals longstanding KOL and President of IASLC. Now look back at all the posts and let it sink in that ORIEN collaborators just may be a portion of the dozens of collaborations that Peregrines CEO Steve King has claimed more than 2 years ago.

Walls are being constructed as we speak and they are made of brick, to stand forever. FDA drug approvals will soon undergo another phase change.... in favor or longer or shorter trials?
: ) No wonder why this is all to the advantage of PS Targeting and if you think flipped PS is not part of ORIEN, think again.

Pay attention to: "It’s growing quicker than we can bring in new members."

Ohio State-led patient database fills national need in cancer research

March 7, 2016

(Ohio State's Dr. Patrick Nana-Sinkam is using ORIEN to develop a blood test that could indicate whether a person is at high risk for lung cancer. )

By Lori Kurtzman The Columbus Dispatch • Saturday February 13, 2016 1:39 PM



If cancer were just one disease — same cause, same treatment — caring for it would be relatively simple. But it's not, not even close. Take two people with the same type of cancer and their diseases can look wildly different.

That's why it's important for cancer researchers to compare similar cases in searching for specific causes and treatments. The challenge has been to find clusters of similar patients, especially considering that they can be scattered across the country, unknown from one hospital to another.

Enter ORIEN. The Oncology Research Information Exchange Network began nearly two years ago as a joint effort between the Ohio State University Comprehensive Cancer Center and the Moffitt Cancer Center in Tampa, Fla.

ORIEN aimed to build a database like nothing cancer researchers had seen before — a huge collection of detailed patient records and blood and tissue samples from cancer patients across the country. Ohio State and Moffitt put up $2 million to establish the network.

It seems to have hit on a need.

Nine additional institutions have signed up, and seven more are working to get in. Recently, ORIEN colleagues including Ohio State's Dr. Michael Caligiuri met with Vice President Joe Biden's staff to talk about how the network could fit into the federal government's push to end cancer.

"We’ve done absolutely nothing" to recruit new institutions, said Caligiuri, director of the Comprehensive Cancer Center and chief executive officer of Ohio State’s Arthur G. James Cancer Hospital. "It’s growing quicker than we can bring in new members."

Nearly 150,000 patients, including almost every OSU cancer patient, have agreed to be part of the database. They donate blood and tumor tissue samples for research studies and consent to make their records available to all ORIEN participants. They also agree to be contacted should a clinical study arise.

So far, in addition to Ohio State and Moffitt, participating institutions include the University of Colorado Cancer Center; Rutgers Cancer Institute of New Jersey; the Henry M. Jackson Foundation for the Advancement of Military Medicine; the University of Virginia Cancer Center; Morehouse School of Medicine; the University of New Mexico Cancer Center; the University of Southern California Norris Comprehensive Cancer Center; City of Hope; and Huntsman Cancer Institute at the University of Utah. Each institution has a full-time employee dedicated to the network, Caligiuri said.

The huge database will allow for much quicker clinical trials, Caligiuri said.

For example, if a pharmaceutical company is looking to test a new drug for a specific form of cancer, rather than recruiting patients at a single institution — and possibly waiting years for appropriate patients to turn up — researchers now can query the database and access a huge pool of people who might fit their criteria.

"I think the mechanism is amazing for researchers and also for patients," said Dr. David Carbone, who leads Ohio State's thoracic oncology center and has used ORIEN for research. "Their information is there if some new therapy comes up."

Carbone said he hopes ORIEN becomes a nationwide network that includes private health-care systems that don't have researchers. Caligiuri said he hopes the network finds the funding it needs to maintain itself and grow.

At the OSU Comprehensive Cancer Center, Dr. Patrick Nana-Sinkam is using ORIEN to develop a blood test that could indicate whether a person is at high risk for lung cancer. He and a team are looking at blood samples from patients at various stages of disease to see what they might have in common.

Nana-Sinkam said he's grateful for the patients who have elected to participate — 15,000 of them from Ohio State.

"They really see this as a partnership," he said, "and that's the way we see it."

[e-mail]

@LoriKurtzman

http://www.dispatch.com/content/stories/local/2016/02/13/osu-led-cancer-patient-database-draws-national-interest.html

Nice to see ORIEN collaborators all puzzle pieces tied into Peregrine...

So far, in addition to Ohio State and Moffitt, participating institutions include the University of Colorado Cancer Center; Rutgers Cancer Institute of New Jersey; the Henry M. Jackson Foundation for the Advancement of Military Medicine; the University of Virginia Cancer Center; Morehouse School of Medicine; the University of New Mexico Cancer Center; the University of Southern California Norris Comprehensive Cancer Center; City of Hope; and Huntsman Cancer Institute at the University of Utah. Each institution has a full-time employee dedicated to the network, Caligiuri said.

The huge database will allow for much quicker clinical trials, Caligiuri said.

For example, if a pharmaceutical company is looking to test a new drug for a specific form of cancer, rather than recruiting patients at a single institution — and possibly waiting years for appropriate patients to turn up — researchers now can query the database and access a huge pool of people who might fit their criteria.

"I think the mechanism is amazing for researchers and also for patients," said Dr. David Carbone, who leads Ohio State's thoracic oncology center and has used ORIEN for research. "Their information is there if some new therapy comes up."

Carbone said he hopes ORIEN becomes a nationwide network that includes private health-care systems that don't have researchers. Caligiuri said he hopes the network finds the funding it needs to maintain itself and grow. ....
...
..

...just taking a look at this map and seeing Rutgers, I guess all can EASILY see why Dr. Raymond Birge is fully backing PS Targeting now...

'ORIEN' Precision Cancer Research Collaboration — Coanchored by Ohio State — Adds Three New Partners
July 09, 2015

http://cancer.osu.edu/news-and-media/news/orien-adds-three-leading-oncology-institutions-to-growing-precision-cancer-research-collaboration